A Food and Drug Administration advisory panel rejected an effort by Pfizer Inc to remove boxed warnings of neuropsychiatric dangers on the label for Chantix the companys smokingcessation drug The committee vote was  in favor of retaining existing warnings with six suggesting modifications and one in favor of removal Several panel members suggested adding sleep disturbances to the warnings  The
  